World
Alkermes’ orexin agonist shows potential to treat ADHD in The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
Dr. Kai NakamuraChief Science CorrespondentPublished Sep 21, 2026 at 1:48 PM EDT · 1 min read
Alkermes’ orexin agonist shows potential to treat ADHD in The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study. The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.